Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817541 | 0.84 | TSHR (0.38) | TSHRLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL10013633 | 0.78 | TSHR (0.38) | TSHRLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL817934 | 0.72 | MMP3 (0.36) | TSHRLMNAALDH1A1HTT | |
| SCHEMBL9913498 | 0.67 | PRKCA (0.35) | ALDH1A1 | |
| SCHEMBL13596762 | 0.65 | TSHR (0.39) | TSHRLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL11305517 | 0.63 | TSHR (0.42) | TSHRLMNAALDH1A1KMT2AEPHX2 | |
| Dimethyl Succinate SCHEMBL28054469 | 0.61 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1MAPT | |
| Dimethyl Succinate SCHEMBL10213 | 0.61 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL14013025 | 0.60 | TSHR (0.50) | TSHRLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL24555876 | 0.59 | PRKCA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653152-B2 | Porous resin bead and method for producing nucleic acid using the same | NITTO DENKO CORPORATION (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120010396-A1 | PRODUCTION METHOD OF POROUS RESIN BEAD | NITTO DENKO CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20110065818-A1 | POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME | NITTO DENKO CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010396-A1 | PRODUCTION METHOD OF POROUS RESIN BEAD | ACMSD, MLN, APEH | TSHR 3729/4885LMNA 4758/4885KDM4E 173/4885 |
| US-20110065818-A1 | POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME | PCNA, ARID2, PARN | TSHR 3703/4885LMNA 1351/4885KDM4E 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.